CFDA’s Fast-Track Orphan Drug Effort Spurs Domestic Firms To In-License
This article was originally published in PharmAsia News
Executive Summary
More Chinese companies are seeking to in-license candidates for rare diseases given a favorable regulatory process and wide commercial opportunity.